Alteogen (XKRX:196170) ROCE % : 50.31% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Alteogen ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alteogen's annualized ROCE % for the quarter that ended in Mar. 2024 was 50.31%.

Alteogen ROCE % Historical Data

The historical data trend for Alteogen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alteogen ROCE % Chart

Alteogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-2.08

-24.71

-10.21

-6.66

-1.89

Alteogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-22.31	65.53	-18.48	-31.91	50.31

Alteogen ROCE % Calculation

Alteogen's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2893.491	/	( ( (245490.136 - 94308.514)	+	(256099.995 - 100415.323) )	/ 2 )
	=	-2893.491	/	( (151181.622	+	155684.672)	/ 2 )
	=	-2893.491	/	153433.147
	=	-1.89 %

Alteogen's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	83628.836	/	( ( (256099.995 - 100415.323)	+	(274622.602 - 97861.538) )	/ 2 )
	=	83628.836	/	( ( 155684.672	+	176761.064 )	/ 2 )
	=	83628.836	/	166222.868
	=	50.31 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Alteogen (XKRX:196170) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alteogen ROCE % Related Terms

Thank you for viewing the detailed overview of Alteogen's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alteogen (XKRX:196170) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alteogen Inc (XKRX:196170) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon, KOR, 34054

Website

http://www.alteogen.com

Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Alteogen (XKRX:196170) Headlines

No Headlines